{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.1","upperLimit":"68.9","value":"61.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (by investigator assessment) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-treated EGFR T790M mutation positive (by central testing) patient cohort. Dose groups were expanded to include more patients.","id":"OG000","title":"Dose Expansion"}],"paramType":"NUMBER","populationDescription":"All pre-treated EGFR T790M mutation positive (by central testing) patients who received at least one dose of AZD9291.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)","title":"Objective Response Rate (ORR) for Dose Expansion Population","type":"PRIMARY","unitOfMeasure":"% of participants"}